CliffBio
small molecule

GANIRELIX ACETATE

GANIRELIX ACETATE

Loss of exclusivity—loss of exclusivity
CompanyAmphastar Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameGANIRELIX ACETATE
Active ingredientGANIRELIX ACETATE
Strength250MCG/0.5ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

More from Amphastar Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

GANIRELIX ACETATE patent cliff — loss of exclusivity — | CliffBio